Lataa...
PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers
HER2 amplification/overexpression (HER2+) frequently co-occurs with PI3K pathway activation in breast tumors. PI3K signaling is most often activated by PIK3CA mutation or PTEN loss, which frequently results in sensitivity to p110α or p110β inhibitors, respectively. To examine the p110 isoform depend...
Tallennettuna:
| Julkaisussa: | Oncogene |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4846581/ https://ncbi.nlm.nih.gov/pubmed/26500061 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2015.406 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|